Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase

Journal of Medicinal Chemistry

Volumn 57, Issue 9, 2014, Pages 3856-3873

  Currie, Kevin S ^a   Kropf, Jeffrey E ^a   Lee, Tony ^a   Blomgren, Peter ^a   Xu, Jianjun ^a   Zhao, Zhongdong ^a   Gallion, Steve ^c   Whitney, J Andrew ^a   Maclin, Deborah ^a,b   Lansdon, Eric B ^c   Maciejewski, Patricia ^a   Rossi, Ann Marie ^a   Rong, Hong ^a   Macaluso, Jennifer ^a   Barbosa, James ^a   Di Paolo, Julie A ^a   Mitchell, Scott A ^a  

^a Gilead Sciences   (United States)

^b GILEAD SCIENCES   (United States)

^c Department of Informatics and Modeling Atheon Pharma Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; FOSTAMATINIB; GS 9973;

ARTICLE; CLINICAL EVALUATION; DRUG EFFICACY;

ADMINISTRATION, ORAL; ANIMALS; CELLS, CULTURED; DRUG DISCOVERY; HUMANS; INDAZOLES; MAGNETIC RESONANCE SPECTROSCOPY; MICE; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZINES; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPLEEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84900343387     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500228a     Document Type: Article

References (55)

1. Mocsai, A.; Ruland, J.; Tybulewicz, V. L. The SYK tyrosine kinase: a crucial player in diverse biological functions Nat. Rev. Immunol. 2010, 10, 387-402
2. Tan, S. L.; Liao, C.; Lucas, M. C.; Stevenson, C.; Demartino, J. A. Targeting the SYK-BTK axis for the treatment of immunological and hematological disorders: recent progress and therapeutic perspectives Pharmacol. Ther. 2013, 138, 294-309
3. Alinari, L.; Christian, B.; Baiocchi, R. A. Novel targeted therapies for mantle cell lymphoma Oncotarget 2012, 3, 203-11
4. Kurosaki, T. Molecular mechanisms in B cell antigen receptor signaling Curr. Opin. Immunol. 1997, 9, 309-318
5. Kurosaki, T. Molecular dissection of B cell antigen receptor signaling Int. J. Mol. Med. 1998, 1, 515-527
6. Kurosaki, T.; Johnson, S. A.; Pao, L.; Sada, K.; Yamamura, H.; Cambier, J. C. Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling J.Exp. Med. 1995, 182, 1815-1823
7. Toapanta, F. R.; Bernal, P. J.; Sztein, M. B. Diverse phosphorylation patterns of B cell receptor-associated signaling in naive and memory human B cells revealed by phosphoflow, a powerful technique to study signaling at the single cell level Front. Cell. Infect. Microbiol. 2012, 2, 128
8. Baba, Y.; Hashimoto, S.; Matsushita, M.; Watanabe, D.; Kishimoto, T.; Kurosaki, T.; Tsukada, S. BLNK mediates Syk-dependent Btk activation Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2582-2586
9. Rivera, J.; Colbert, R. A. Healing the Syk through kinase inhibitors N. Engl. J. Med. 2010, 363, 1362-1364
10. Navarro-Millan, I.; Curtis, J. R. Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritis Curr. Opin. Rheumatol. 2013, 25, 384-390
11. Sullivan, S. D.; Alfonso-Cristancho, R.; Carlson, J.; Mallya, U.; Ringold, S. Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review J. Med. Econ. 2013, 16, 391-396
12. Ruzza, P.; Biondi, B.; Calderan, A. Therapeutic prospect of Syk inhibitors Expert Opin. Ther. Pat. 2009, 19, 1361-1376
13. Moretto, A. F.; Dehnhardt, C.; Kaila, N.; Papaioannou, N.; Thorarensen, A. The 2010 patent landscape for spleen tyrosine kinase inhibitors Recent Pat. Inflammation Allergy Drug Discovery 2012, 6, 97-120
14. Singh, R.; Masuda, E. S.; Payan, D. G. Discovery and development of spleen tyrosine kinase (SYK) inhibitors J. Med. Chem. 2012, 55, 3614-3643
15. Braselmann, S.; Taylor, V.; Zhao, H.; Wang, S.; Sylvain, C.; Baluom, M.; Qu, K.; Herlaar, E.; Lau, A.; Young, C.; Wong, B. R.; Lovell, S.; Sun, T.; Park, G.; Argade, A.; Jurcevic, S.; Pine, P.; Singh, R.; Grossbard, E. B.; Payan, D. G.; Masuda, E. S. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation J. Pharmacol. Exp. Ther. 2006, 319, 998-1008
16. Coffey, G.; DeGuzman, F.; Inagaki, M.; Pak, Y.; Delaney, S. M.; Ives, D.; Betz, A.; Jia, Z. J.; Pandey, A.; Baker, D.; Hollenbach, S. J.; Phillips, D. R.; Sinha, U. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis J. Pharmacol. Exp. Ther. 2012, 340, 350-359
17. Liddle, J.; Atkinson, F. L.; Barker, M. D.; Carter, P. S.; Curtis, N. R.; Davis, R. P.; Douault, C.; Dickson, M. C.; Elwes, D.; Garton, N. S.; Gray, M.; Hayhow, T. G.; Hobbs, C. I.; Jones, E.; Leach, S.; Leavens, K.; Lewis, H. D.; McCleary, S.; Neu, M.; Patel, V. K.; Preston, A. G.; Ramirez-Molina, C.; Shipley, T. J.; Skone, P. A.; Smithers, N.; Somers, D. O.; Walker, A. L.; Watson, R. J.; Weingarten, G. G. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor Bioorg. Med. Chem. Lett. 2011, 21, 6188-6194
18. Liao, C.; Hsu, J.; Kim, Y.; Hu, D-Q.; Xu, D.; Zhang, J.; Pachine, A.; Menke, J.; Whittard, T.; Romero, N.; Truitt, T.; Slade, M.; Lukacs, C.; Hermann, J.; Zhou, M.; Lucas, M.; Narula, S.; DeMartino, J.; Tan, S-L. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy Arthritis Res. Ther. 2013, 15 (R146) 1-14
19. Cha, H. S.; Boyle, D. L.; Inoue, T.; Schoot, R.; Tak, P. P.; Pine, P.; Firestein, G. S. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes J. Pharmacol. Exp. Ther. 2006, 317, 571-578
20. Norman, P. Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors Expert Opin. Ther. Pat. 2012, 22, 335-339
21. Pine, P. R.; Chang, B.; Schoettler, N.; Banquerigo, M. L.; Wang, S.; Lau, A.; Zhao, F.; Grossbard, E. B.; Payan, D. G.; Brahn, E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor Clin. Immunol. 2007, 124, 244-257
22. Bahjat, F. R.; Pine, P. R.; Reitsma, A.; Cassafer, G.; Baluom, M.; Grillo, S.; Chang, B.; Zhao, F. F.; Payan, D. G.; Grossbard, E. B.; Daikh, D. I. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus Arthritis Rheum. 2008, 58, 1433-1444
23. Deng, G. M.; Liu, L.; Bahjat, F. R.; Pine, P. R.; Tsokos, G. C. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice Arthritis Rheum. 2010, 62, 2086-2092
24. Smith, J.; McDaid, J. P.; Bhangal, G.; Chawanasuntorapoj, R.; Masuda, E. S.; Cook, H. T.; Pusey, C. D.; Tam, F. W. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis J. Am. Soc. Nephrol. 2010, 21, 231-236
25. Colonna, L.; Catalano, G.; Chew, C.; DAgati, V.; Thomas, J. W.; Wong, F. S.; Schmitz, J.; Masuda, E. S.; Reizis, B.; Tarakhovsky, A.; Clynes, R. Therapeutic targeting of Syk in autoimmune diabetes J. Immunol. 2010, 185, 1532-1543
26. Podolanczuk, A.; Lazarus, A. H.; Crow, A. R.; Grossbard, E.; Bussel, J. B. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk Blood 2009, 113, 3154-3160
27. Matsubara, S.; Koya, T.; Takeda, K.; Joetham, A.; Miyahara, N.; Pine, P.; Masuda, E. S.; Swasey, C. H.; Gelfand, E. W. Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation Am. J. Respir. Cell Mol. Biol. 2006, 34, 426-433
28. Matsubara, S.; Li, G.; Takeda, K.; Loader, J. E.; Pine, P.; Masuda, E. S.; Miyahara, N.; Miyahara, S.; Lucas, J. J.; Dakhama, A.; Gelfand, E. W. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness Am. J. Respir. Crit. Care Med. 2006, 173, 56-63
29. Fruchon, S.; Kheirallah, S.; Al Saati, T.; Ysebaert, L.; Laurent, C.; Leseux, L.; Fournie, J. J.; Laurent, G.; Bezombes, C. Involvement of the Syk-mTOR pathway in follicular lymphoma cell invasion and angiogenesis Leukemia 2012, 26, 795-805
30. Suljagic, M.; Longo, P. G.; Bennardo, S.; Perlas, E.; Leone, G.; Laurenti, L.; Efremov, D. G. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Emu- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling Blood 2010, 116, 4894-4905
31. Young, R. M.; Hardy, I. R.; Clarke, R. L.; Lundy, N.; Pine, P.; Turner, B. C.; Potter, T. A.; Refaeli, Y. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target Blood 2009, 113, 2508-2516
32. Morales-Torres, J. The status of fostamatinib in the treatment of rheumatoid arthritis Expert Rev. Clin. Immunol. 2012, 8, 609-615
33. Fleischmann, R.; Cutolo, M.; Genovese, M. C.; Lee, E. B.; Kanik, K. S.; Sadis, S.; Connell, C. A.; Gruben, D.; Krishnaswami, S.; Wallenstein, G.; Wilkinson, B. E.; Zwillich, S. H. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs Arthritis Rheum. 2012, 64, 617-629
34. Weinblatt, M. E.; Kavanaugh, A.; Burgos-Vargas, R.; Dikranian, A. H.; Medrano-Ramirez, G.; Morales-Torres, J. L.; Murphy, F. T.; Musser, T. K.; Straniero, N.; Vicente-Gonzales, A. V.; Grossbard, E. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial Arthritis Rheum. 2008, 58, 3309-3318
35. Weinblatt, M. E.; Kavanaugh, A.; Genovese, M. C.; Musser, T. K.; Grossbard, E. B.; Magilavy, D. B. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis N. Engl. J. Med. 2013, 363, 1303-1312
36. AstraZeneca. AstraZeneca announces top-line results from phase III OSKIRA trials of FOSTAMATINIB and decision not to proceed with regulatory filings. http://www.astrazeneca.com/Media/Press-releases/Article/20130504-astrazeneca- announces-topline-results-from-phase-iii-o; press release, June 4, 2013.
37. AstraZeneca. AstraZeneca announces top-line results of OSKIRA-4 phase IIb study of fostamatinib as a monotherapy for rheumatoid arthritis. http://www.astrazeneca.com/Media/Press-releases/Article/20121213-AstraZeneca- announces-results-OSKIRA-4-study-fostamatinib; press release, December 13, 2012.
38. AstraZeneca. AstraZeneca announces top-line results from OSKIRA-1 phase III study of fostamatinib in rheumatoid arthritis. http://www.astrazeneca.com/ Media/Press-releases/Article/20130405 - astrazeneca-announces-topline-results- from-oskira1; press release, April 5, 2013.
39. Friedberg, J. W.; Sharman, J.; Sweetenham, J.; Johnston, P. B.; Vose, J. M.; Lacasce, A.; Schaefer-Cutillo, J.; De Vos, S.; Sinha, R.; Leonard, J. P.; Cripe, L. D.; Gregory, S. A.; Sterba, M. P.; Lowe, A. M.; Levy, R.; Shipp, M. A. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 2010, 115, 2578-2585
40. Park, S. R.; Speranza, G.; Piekarz, R.; Wright, J. J.; Kinders, R. J.; Wang, L.; Pfister, T.; Trepel, J. B.; Lee, M. J.; Alarcon, S.; Steinberg, S. M.; Collins, J.; Doroshow, J. H.; Kummar, S. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas Cancer Chemother. Pharmacol. 2013, 71, 981-990
41. Jin, F.; DiPaolo, J. A.; Shao-Li, X.; Yellin, O.; Hawkins, M. J.; Ramanathan, S. Evaluation of the safety, pharmacokinetics and pharmacodynamics of GS-9973, a novel SYK inhibitor, and GS-1101, a novel PI3K? inhibitor, when administered alone or in combination in humans. Presented at the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, Apr 6-10, 2013.
42. McAdoo, S. P.; Tam, F. W. Fostamatinib disodium Drugs Future 2011, 36, 273
43. Krishnan, S.; Juang, Y. T.; Chowdhury, B.; Magilavy, A.; Fisher, C. U.; Nguyen, H.; Nambiar, M. P.; Kyttaris, V.; Weinstein, A.; Bahjat, R.; Pine, P.; Rus, V.; Tsokos, G. C. Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells J. Immunol. 2008, 181, 8145-8152
44. Mitchell, S. A.; Currie, K. S.; Blomgren, P. A.; Kropf, J. E.; Lee, S. H.; Xu, J.; Stafford, D. G.; Harding, J. P.; Barbosa, Jr, A. J.; Zhao, Z. PCT Int. Appl. WO2010068257, 2010.
45. Yamamoto, N.; Takeshita, K.; Shichijo, M.; Kokubo, T.; Sato, M.; Nakashima, K.; Ishimori, M.; Nagai, H.; Li, Y-F.; Yura, T.; Bacon, K. B. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)- imidazo-[1,2 c ]pyrimidine-5-ylamino]-nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rats J. Pharm. Exp. Ther. 2003, 306, 1174-1181
46. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051
47. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P. A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 2008, 26, 127-132
48. Patani, G. A.; LaVoie, E. J. Bioisosterism: a rational approach in drug design Chem. Rev. 1996, 96, 3147-3176
49. Ballatore, C.; Huryn, D. M.; Smith, A. B., III. Carboxylic acid (bio)isosteres in drug design ChemMedChem 2013, 8, 385-395
50. Herr, R. J. 5-Substituted-1H-tetrazoles as carboxylic acid isosteres: medicinal chemistry and synthetic methods Bioorg. Med. Chem. 2002, 10, 3379-3393
51. Lucas, M. C.; Goldstein, D. M.; Hermann, J. C.; Kuglstatter, A.; Liu, W.; Luk, K. C.; Padilla, F.; Slade, M.; Villaseñor, A. G.; Wanner, J.; Xie, W.; Zhang, X.; Liao, C. Rational design of highly selective spleen tyrosine kinase inhibitors J. Med. Chem. 2012, 55, 10414-10423
52. Tu, M.; Rai, B. K.; Mathiowetz, A. M.; Didiuk, M.; Pfefferkorn, J. A.; Guzman-Perez, A.; Benbow, J.; Guimaraes, C. R. W.; Mente, S.; Hayward, M. M. Exploring aromatic chemical space with NEAT: novel and electronically equivalent aromatic template J. Chem. Inf. Model. 2012, 52, 1114-1123
53. Villaseñor, A. G.; Kondru, R.; Ho, H.; Wang, S.; Papp, E.; Shaw, D.; Barnett, J. W.; Browner, J. W.; Kuglstatter, A. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes Chem. Biol. Drug Des. 2009, 73, 466-470
54. Harris, P. A.; Boloor, A.; Cheung, M.; Kumar, R.; Crosby, R. M.; Davis-Ward, R. G.; Epperly, A. H.; Hinkle, K. W.; Hunter, R. N., 3rd; Johnson, J. H.; Knick, V. B.; Laudeman, C. P.; Luttrell, D. K.; Mook, R. A.; Nolte, R. T.; Rudolph, S. K.; Szewczyk, J. R.; Truesdale, A. T.; Veal, J. M.; Wang, L.; Stafford, J. A. Discovery of 5-[[4-[(2,3-dimethyl-2 H -indazol-6-yl)methylamino] -2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor J. Med. Chem. 2008, 51, 4632-4640
55. Ramanathan, S.; DiPaolo, J. A.; Doan, T.; Burge, D. Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor. Presented at the 104th Annual Meeting of the American Association for Cancer Research, Washington, DC, Apr 6-10, 2013.